BMS Selects Medidata Clinical Cloud

Medidata’s Technology Platform and Data Analytics Maximize Value of Clinical Data, Enhance Trial Design and Execution, and Enable More Agility in Drug Development

  NEW YORK, N.Y.– April 20, 2016 – Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Bristol-Myers Squibb has selected the Medidata Clinical Cloud to help manage, monitor and analyze its clinical trials. Medidata’s cutting-edge technology platform will support Bristol-Myers Squibb’s research capabilities in immuno-oncology, oncology, immunoscience, virology, cardiovascular, fibrotic diseases, genetically modified diseases and metabolics.   The Medidata platform has been used by more than 630 customers around the world – supporting more than 11,000 clinical studies, 420,000 investigational sites and more than 3.1 million trial volunteers – driving a transformation in clinical trial design and execution, leading to better science and new medical breakthroughs for patients. Bristol-Myers Squibb will integrate Medidata’s data management, data analytics and risk-based monitoring (RBM) capabilities into all stages of its drug development process.   “Our agreement with Bristol-Myers Squibb is a great example of how the world’s best clinical researchers are increasingly relying on Medidata technology to help support advances in treatments for patients,” said Medidata’s chief executive officer Tarek Sherif. “Medidata has developed the most comprehensive cloud platform dedicated to clinical research, powered by the world’s largest data repository. With our powerful and flexible SaaS solution, we are helping our customers achieve meaningful time-to-market results, as well as giving them the data and actionable insights they need to innovate successfully.”   In adopting the Medidata Clinical Cloud platform across therapeutic areas, Bristol-Myers Squibb will utilize a full suite of Medidata solutions, including Medidata Rave® for electronic data capture, management and reporting and Medidata’s RBM solutions, Medidata TSDV and Medidata CSA, enabling better prioritization of resources around key areas of risk, such as patient safety and data quality and integrity.   A phased rollout is under way. Medidata has selected Accenture, a leading global professional services company providing a broad range of services and solutions in strategy, consulting, digital, technology and operations, to be its partner for specific elements of the transformation project.   

About Medidata

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. We are committed to advancing the competitive and scientific goals of our life sciences customers worldwide: more than 600 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations. Our industry-leading technology platform, the Medidata Clinical Cloud, is the primary technology solution powering clinical trials for 17 of the world's top 25 global pharmaceutical companies, bringing new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting.